I. Charreau

发表

Adverse Reactions to Cotrimoxazole in HIV-infected Patients: Predictive Factors and Subsequent HIV Disease Progression

F. Raffi, C. Leport, P. Yeni, 2001, Scandinavian Journal of Infectious Diseases.

HIV-1 RNA response to antiretroviral treatment in 1280 participants in the Delta Trial: an extended virology study.

D. Jeffries, A. Breckenridge, F. Brun-Vézinet, 1999, AIDS.

Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study.

M. Wainberg, C. Delaugerre, C. Tremblay, 2017, The lancet. HIV.

Changes in kidney function among men having sex with men starting on demand tenofovir disoproxil fumarate – emtricitabine for HIV pre‐exposure prophylaxis

C. Tremblay, F. Raffi, L. Meyer, 2020, Journal of the International AIDS Society.

Decreases in inflammatory and coagulation biomarkers levels in HIV-infected patients switching from enfuvirtide to raltegravir: ANRS 138 substudy.

J. Molina, S. Mourah, F. Caron, 2013, The Journal of infectious diseases.

Low-dose ritonavir-boosted darunavir in virologically suppressed HIV-1-infected adults: an open-label trial (ANRS 165 Darulight)

R. Tubiana, C. Katlama, Y. Yazdanpanah, 2018, The Journal of antimicrobial chemotherapy.

Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial.

C. Delaugerre, J. Molina, S. Gallien, 2011, The Journal of antimicrobial chemotherapy.

Risk Factors for Esophageal Candidiasis in a Large Cohort of HIV-Infected Patients Treated with Nucleoside Analogues

P. Yeni, J. Reynes, S. Abgrall, 2001, European Journal of Clinical Microbiology and Infectious Diseases.

Single-dose pharmacokinetics and pharmacodynamics of oral tenofovir and emtricitabine in blood, saliva and rectal tissue: a sub-study of the ANRS IPERGAY trial

C. Delaugerre, F. Mammano, L. Meyer, 2017, The Journal of antimicrobial chemotherapy.

Oral abstracts of the 21st International AIDS Conference 18–22 July 2016, Durban, South Africa

Michael I. Jordan, Donald A. Jackson, J. G. Ndirangu, 2016, Journal of the International AIDS Society.

Costs and benefits of On-Demand HIV Pre-Exposure Prophylaxis in Men Who Have Sex with Men Analysis of the ANRS IPERGAY study with a one-year follow-up.

C. Tremblay, I. Durand-zaleski, B. Spire, 2018, AIDS.

Inflammatory Markers During Early Treatment of Seroconverters in a Randomized Placebo-Controlled Trial of PrEP (ANRS-IPERGAY)

C. Delaugerre, L. Meyer, D. Carette, 2021, Open forum infectious diseases.

Incidence and risk factors for liver enzymes elevations in highly treatment-experienced patients switching from enfuvirtide to raltegravir: a sub-study of the ANRS-138 EASIER trial

J. Molina, J. Braun, J. Viard, 2016, AIDS research and therapy.

Incidence and risk factors for liver enzymes elevations in highly treatment-experienced patients switching from enfuvirtide to raltegravir: a sub-study of the ANRS-138 EASIER trial

J. Molina, J. Braun, J. Viard, 2016, AIDS Research and Therapy.

Emerging integrase inhibitor resistance mutations in raltegravir-treated HIV-1-infected patients with low-level viremia

D. Kuritzkes, C. Delaugerre, J. Molina, 2011, AIDS.

High Concentration of Raltegravir in Semen of HIV-Infected Men: Results from a Substudy of the EASIER-ANRS 138 Trial

C. Delaugerre, J. Molina, V. Furlan, 2009, Antimicrobial Agents and Chemotherapy.

Early diagnosis and risk factors of acute hepatitis c in high-risk men who have sex with men on pre-exposure prophylaxis.

C. Delaugerre, C. Tremblay, F. Raffi, 2020, AIDS.

Effect of two injections of non-adjuvanted influenza A H1N1pdm2009 vaccine in renal transplant recipients: INSERM C09-32 TRANSFLUVAC trial.

B. Autran, E. Morelon, D. Bottigioli, 2012, Vaccine.

On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial.

C. Delaugerre, C. Tremblay, F. Raffi, 2019, The lancet. HIV.

On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection.

David Thompson, Laurence Meyer, Jean-Pierre Aboulker, 2015, The New England journal of medicine.

Incidence and Risk Factors of Thrombocytopenia in Patients Receiving Intermittent Antiretroviral Therapy: A Substudy of the ANRS 106-Window Trial

C. Katlama, P. Bierling, P. Morlat, 2009, Journal of acquired immune deficiency syndromes.

First analysis of tumor regression for the European randomized trial of etanidazole combined with radiotherapy in head and neck carcinomas.

F. Eschwège, E. Malaise, H. Sancho-garnier, 1992, International journal of radiation oncology, biology, physics.

Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine.

C. Delaugerre, J. Molina, S. Gallien, 2015, The Journal of antimicrobial chemotherapy.

Prevalence and incidence of HPV infection in men having sex with men enrolled in a PrEP study: A sub-study of the ANRS IPERGAY trial.

C. Delaugerre, C. Tremblay, L. Meyer, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Intermittent antiretroviral therapy in patients with controlled HIV infection.

J. Ragnaud, J. Izopet, J. Molina, 2007, AIDS.

High Prevalence and High Rate of Antibiotic Resistance of Mycoplasma genitalium Infections in Men who Have Sex with Men. A Sub-Study of the ANRS Ipergay PrEP Trial.

C. Delaugerre, B. Berçot, F. Raffi, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Incidence and risk factors for recurrent sexually transmitted infections among MSM on HIV pre-exposure prophylaxis

C. Delaugerre, F. Raffi, B. Spire, 2022, AIDS.

Early diagnosis and risk factors of acute hepatitis C in high-risk MSM on preexposure prophylaxis.

C. Delaugerre, C. Tremblay, F. Raffi, 2020 .

International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK

Samit R. Joshi, Charlene A Flash, Thomas Lengauer, 2014 .

Time course of total HIV-1 DNA and 2-long-terminal repeat circles in patients with controlled plasma viremia switching to a raltegravir-containing regimen

C. Delaugerre, J. Molina, P. Yeni, 2010, AIDS.

Progress report of a phase II and a phase III trial with etanidazole (SR-2508): a multicentre European study.

F. Eschwège, E. Malaise, H. Sancho-garnier, 1991, Radiotherapy and Oncology.

Toxoplasma gondii infection in advanced HIV infection

É. Oksenhendler, Claude Carbón, J. Aboulker, 1994, AIDS.

Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial.

C. Delaugerre, B. Berçot, F. Raffi, 2017, The Lancet. Infectious diseases.

Risk factors for HIV infection among men who have sex with men in the ANRS IPERGAY PrEP trial

C. Delaugerre, F. Raffi, B. Spire, 2021, Sexually Transmitted Infections.

Changes in Sexual Behaviors in Men Who Have Sex with Men: A Comparison Between the Double-Blind and Open-Label Extension Phases of the ANRS-IPERGAY Trial

C. Delaugerre, A. Chamberland, H. Melliez, 2020, AIDS and Behavior.

Costs and benefits of On-Demand HIV Pre-Exposure Prophylaxis in Men Who Have Sex with Men Analysis of the ANRS IPERGAY study with a one-year follow-up.

C. Tremblay, I. Durand-zaleski, B. Spire, 2017, AIDS.

Effect of On-Demand Oral Pre-exposure Prophylaxis With Tenofovir/Emtricitabine on Herpes Simplex Virus-1/2 Incidence Among Men Who Have Sex With Men: A Substudy of the ANRS IPERGAY Trial

M. Wainberg, C. Delaugerre, C. Tremblay, 2018, Open forum infectious diseases.

Estimated pill intake with on-demand PrEP with oral TDF/FTC using TFV-DP concentration in dried blood spots in the ANRS IPERGAY trial.

C. Delaugerre, L. Meyer, L. Cotte, 2021, The Journal of antimicrobial chemotherapy.

Drug resistance among patients who acquired HIV infection in a preexposure prophylaxis trial

C. Delaugerre, D. Carette, L. Cotte, 2018, AIDS.

Oral contraceptive use and risk of benign breast disease in a French case-control study of young women.

G. Contesso, J. Guinebretière, A. Bachelot, 1993, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

HIV-1-Resistant Strains during 8-Week on 8-Week off Intermittent Therapy and their Effect on CD4+ T-cell Counts and Antiviral Response

J. Izopet, J. Molina, B. Marchou, 2008, Antiviral therapy.

Comparison of resistance mutation patterns in historical plasma HIV RNA genotypes with those in current proviral HIV DNA genotypes among extensively treated patients with suppressed replication

C. Delaugerre, B. Marchou, J. Braun, 2012, HIV medicine.

Presence of Lamivudine or Emtricitabine Is Associated with Reduced Emergence of Nonnucleoside Reverse Transcriptase Inhibitor Mutations in an Efavirenz-Based Intermittent Antiretroviral Treatment Regimen

J. Izopet, J. Molina, B. Marchou, 2011, Antimicrobial Agents and Chemotherapy.

Ultra-deep sequencing improves the detection of drug resistance in cellular DNA from HIV-infected patients on ART with suppressed viraemia

C. Delaugerre, J. Molina, M. Chaix, 2018, The Journal of antimicrobial chemotherapy.

Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial.

C. Delaugerre, C. Katlama, Y. Yazdanpanah, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Structured Treatment Interruptions in Primary HIV-1 Infection: The ANRS 100 PRIMSTOP Trial

C. Rouzioux, B. Hoen, F. Raffi, 2005, Journal of acquired immune deficiency syndromes.

Costs of Intermittent Versus Continuous Antiretroviral Therapy in Patients With Controlled HIV Infection: A Substudy of the ANRS 106 Window Trial

I. Durand-zaleski, J. Molina, B. Marchou, 2008, Journal of acquired immune deficiency syndromes.

Impact on Health-Related Quality of Life of a Switch From Enfuvirtide to Raltegravir Among Multidrug-Resistant HIV-1–Infected Patients: A Randomized Open-Label Trial (EASIER-ANRS 138)

P. Morlat, B. Spire, J. Molina, 2010, HIV clinical trials.

Pharmacokinetic modelling of darunavir/ritonavir dose reduction (800/100 to 400/100 mg once daily) in a darunavir/ritonavir-containing regimen in virologically suppressed HIV-infected patients: ANRS 165 DARULIGHT sub-study

R. Tubiana, C. Katlama, Y. Yazdanpanah, 2018, The Journal of antimicrobial chemotherapy.

Hepatitis A and B vaccine uptake and immunisation among men who have sex with men seeking PrEP: a substudy of the ANRS IPERGAY trial

C. Delaugerre, F. Raffi, B. Spire, 2022, Sexually Transmitted Infections.

Prevalence and incidence of HEV among men using HIV pre-exposure prophylaxis: A sub-study of the ANRS IPERGAY trial.

C. Delaugerre, F. Raffi, L. Meyer, 2023, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Intention-to-treat vs. on-treatment analyses of clinical trial data: experience from a study of pyrimethamine in the primary prophylaxis of toxoplasmosis in HIV-infected patients. ANRS 005/ACTG 154 Trial Group.

R. Salamon, B. Luft, C. Leport, 1998, Controlled clinical trials.